p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis

References

• Chene P. The role of tetramerization in p53 function. Oncogene 2001; 20:2611-7; PMID:11420672; http://dx.doi.org/10.1038/sj.onc.1204373
   PubMed Web of Science ®Google Scholar
• Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006; 22:741-53; PMID:16793544; http://dx.doi.org/10.1016/j.molcel.2006.05.015
   PubMed Web of Science ®Google Scholar
• Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 2014; 14:359-70; PMID:24739573; http://dx.doi.org/10.1038/nrc3711
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/10.1038/356215a0
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012; 26:1268-86; PMID:22713868; http://dx.doi.org/10.1101/gad.190678.112
   PubMed Web of Science ®Google Scholar
• Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9:749-58; PMID:19776744; http://dx.doi.org/10.1038/nrc2723
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014; 25:304-17; PMID:24651012; http://dx.doi.org/10.1016/j.ccr.2014.01.021
   PubMed Web of Science ®Google Scholar
• Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100:8424-9; PMID:12826609; http://dx.doi.org/10.1073/pnas.1431692100
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Kato S, Otsuka K, Watanabe G, Kumabe T, Tominaga T, Yoshimoto T, Ishioka C. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library. Oncogene 2005; 24:6976-81; PMID:16007150; http://dx.doi.org/10.1038/sj.onc.1208839
   PubMed Web of Science ®Google Scholar
• Malkin D. Li-Fraumeni syndrome. Genes Cancer 2011; 2:475-84; PMID:21779515; http://dx.doi.org/10.1177/1947601911413466
   PubMedGoogle Scholar
• Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene 1998; 17:643-9; PMID:9704930; http://dx.doi.org/10.1038/sj.onc.1201974
   PubMed Web of Science ®Google Scholar
• Warnock LJ, Knox A, Mee TR, Raines SA, Milner J. Influence of tetramerisation on site-specific post-translational modifications of p53: a comparison of human and murine p53 tumor suppressor protein. Cancer Biol Ther 2008; 7:1481-9; PMID:18769132; http://dx.doi.org/10.4161/cbt.7.9.6473
   PubMed Web of Science ®Google Scholar
• Itahana Y, Ke H, Zhang Y. p53 oligomerization is essential for its C-terminal lysine acetylation. J Biol Chem 2009; 284:5158-64; PMID:19106109; http://dx.doi.org/10.1074/jbc.M805696200
   PubMed Web of Science ®Google Scholar
• Lee IH, Kawai Y, Fergusson MM, Rovira II, Bishop AJ, Motoyama N, Cao L, Finkel T. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science 2012; 336:225-8; PMID:22499945; http://dx.doi.org/10.1126/science.1218395
   PubMed Web of Science ®Google Scholar
• Ono W, Hayashi Y, Yokoyama W, Kuroda T, Kishimoto H, Ito I, Kimura K, Akaogi K, Waku T, Yanagisawa J. The nucleolar protein Myb-binding protein 1A (MYBBP1A) enhances p53 tetramerization and acetylation in response to nucleolar disruption. J Biol Chem 2014; 289:4928-40; PMID:24375404; http://dx.doi.org/10.1074/jbc.M113.474049
   PubMed Web of Science ®Google Scholar
• Meng X, Yue J, Liu Z, Shen Z. Abrogation of the transactivation activity of p53 by BCCIP down-regulation. J Biol Chem 2007; 282:1570-1576; PMID:17135243; http://dx.doi.org/10.1074/jbc.M607520200
   PubMed Web of Science ®Google Scholar
• Xu J, Zhou X, Wang J, Li Z, Kong X, Qian J, Hu Y, Fang JY. RhoGAPs attenuate cell proliferation by direct interaction with p53 tetramerization domain. Cell Rep 2013; 3:1526-38; PMID:23684608; http://dx.doi.org/10.1016/j.celrep.2013.04.017
   PubMed Web of Science ®Google Scholar
• Lui K, Sheikh MS, Huang Y. Regulation of p53 oligomerization by Ras superfamily protein RBEL1A. Genes Cancer 2015; 6:307-16; PMID:26413214
   PubMedGoogle Scholar
• van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 2009; 284:13804-11; PMID:19297317; http://dx.doi.org/10.1074/jbc.M901351200
   PubMed Web of Science ®Google Scholar
• Foo RS, Nam YJ, Ostreicher MJ, Metzl MD, Whelan RS, Peng CF, Ashton AW, Fu W, Mani K, Chin SF, et al. Regulation of p53 tetramerization and nuclear export by ARC. Proc Natl Acad Sci USA 2007; 104:20826-31; PMID:18087040; http://dx.doi.org/10.1073/pnas.0710017104
   PubMed Web of Science ®Google Scholar
• Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol 1994; 1:877-90; PMID:7773777; http://dx.doi.org/10.1038/nsb1294-877
   PubMedGoogle Scholar
• Jeffrey PD, Gorina S, Pavletich NP. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Å. Science 1995; 267:1498-502; PMID:7878469; http://dx.doi.org/10.1126/science.7878469
   PubMed Web of Science ®Google Scholar
• Nicholls CD, McClure KG, Shields MA, Lee PWK. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. J Biol Chem 2002; 277:12937-45; PMID:11805092; http://dx.doi.org/10.1074/jbc.M108815200
   PubMed Web of Science ®Google Scholar
• Weinberg RL, Veprintsev DB, Fersht AR. Cooperative binding of tetrameric p53 to DNA. J Mol Biol 2004; 341:1145-59; PMID:15321712; http://dx.doi.org/10.1016/j.jmb.2004.06.071
   PubMed Web of Science ®Google Scholar
• Ma L, Wagner J, Rice JJ, Hu W, Levine AJ, Stolovitzky GA. A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci USA 2005; 102:14266-71; PMID:16186499; http://dx.doi.org/10.1073/pnas.0501352102
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Huang F, Fersht AR. Single-molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res 2011; 29:2294-303; http://dx.doi.org/10.1093/nar/gkq800
   Web of Science ®Google Scholar
• Gaglia G, Guan Y, Shah JV, Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci USA 2013; 110:15497-501; PMID:24006363; http://dx.doi.org/10.1073/pnas.1311126110
   PubMed Web of Science ®Google Scholar
• Davison TS, Nie X, Ma W, Lin Y, Kay C, Benchimol S, Arrowsmith CH. Structure and functionality of a designed p53 dimer. J Mol Biol 2001; 307:605-17; PMID:11254385; http://dx.doi.org/10.1006/jmbi.2001.4450
   PubMed Web of Science ®Google Scholar
• Poon GM, Brokx RD, Sung M, Gariépy J. Tandem dimerization of the human p53 tetramerization domain stabilizes a primary dimer intermediate and dramatically enhances its oligomeric stability. J Mol Biol 2007; 365:1217-31; PMID:17113101; http://dx.doi.org/10.1016/j.jmb.2006.10.051
   PubMed Web of Science ®Google Scholar
• Brokx RD, Bolewska-Pedyczak E, Gariépy J. A stable human p53 heterotetramer based on constructive charge interactions within the tetramerization domain. J Biol Chem 2003; 278:2327-32; PMID:12433927; http://dx.doi.org/10.1074/jbc.M208528200
   PubMed Web of Science ®Google Scholar
• Lang V, Pallara C, Zabala A, Lobato-Gil S, Lopitz-Otsoa F, Farrás R, Hjerpe R, Torres-Ramos M, Zabaleta L, Blattner C, et al. Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity. Mol Oncol 2014; 8:1026-42; PMID:24816189; http://dx.doi.org/10.1016/j.molonc.2014.04.002
   PubMed Web of Science ®Google Scholar
• Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A, Rosenwald A, Elsässer HP, Stiewe T. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 2013; 30:1512-25; http://dx.doi.org/10.1016/j.celrep.2013.04.008
   Web of Science ®Google Scholar
• Li T, Kon N, Tan M, Ludwig T, Zhao Y, Baer R, Wei G. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012; 149:1269-83; PMID:22682249; http://dx.doi.org/10.1016/j.cell.2012.04.026
   PubMed Web of Science ®Google Scholar
• Igarashi H, Hirano H, Yahagi A, Saika T, Ishihara K. Anti-apoptotic roles for the mutant p53R248Q through suppression of p53-regulated apoptosis-inducing protein 1 in the RA-derived fibroblast-like synoviocyte cell line MH7A. Clin Immunol 2014; 150:12-21; PMID:24316591; http://dx.doi.org/10.1016/j.clim.2013.10.013
   PubMed Web of Science ®Google Scholar
• Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL, Cheah PY, Sabapathy K. Amino-terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. Proc Natl Acad Sci USA 2015; 112:E6349-58; PMID:26578795; http://dx.doi.org/10.1073/pnas.1510043112
   PubMed Web of Science ®Google Scholar
• Beckerman R, Yoh K, Mattia-Sansobrino M, Zupnick A, Laptenko O, Karni-Schmidt O, Ahn J, Byeon I, Keezer S, Prives C. Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. Cell Cycle 2016; 15:1425-38; PMID:27210019; http://dx.doi.org/10.1080/15384101.2016.1170270
   PubMed Web of Science ®Google Scholar
• Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014; 13:217-36; PMID:24577402; http://dx.doi.org/10.1038/nrd4288
   PubMed Web of Science ®Google Scholar
• Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tikino T, Nakamaru Y, et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by ser-46 phosphorylated p53. Cell 2000; 102:849-62; PMID:11030628; http://dx.doi.org/10.1016/S0092-8674(00)00073-8
   PubMed Web of Science ®Google Scholar
• Zhang XP, Liu F, Cheng Z, Wang W. Cell fate decision mediated by p53 pulses. Proc Natl Acad Sci USA 2009; 106:12245-50; PMID:19617533; http://dx.doi.org/10.1073/pnas.0813088106
   PubMed Web of Science ®Google Scholar
• Chen X, Chen J, Gan S, Guan G, Zhou Y, Ouyang Q, Shi J. DNA damage strength modulates a bimodal switch of p53 dynamics for cell-fate control. BMC Biol 2013; 11:73; PMID:23800173; http://dx.doi.org/10.1186/1741-7007-11-73
   PubMed Web of Science ®Google Scholar
• Zhang XP, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 2011; 108:8990-5; PMID:21576488; http://dx.doi.org/10.1073/pnas.1100600108
   PubMed Web of Science ®Google Scholar
• Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002; 62:2883-9; PMID:12019168
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; PMID:8242752; http://dx.doi.org/10.1016/0092-8674(93)90500-P
   PubMed Web of Science ®Google Scholar
• Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90; PMID:7585571
   PubMed Web of Science ®Google Scholar